Scarica l'app Stockscreener
40.89
4.66%
1.82
Precedente Chiudi:
$39.07
Aprire:
$38.53
Volume 24 ore:
1.69M
Relative Volume:
2.24
Capitalizzazione di mercato:
$3.17B
Reddito:
$399.58M
Utile/perdita netta:
$-54.04M
Rapporto P/E:
-102.22
EPS:
-0.4
Flusso di cassa netto:
$40.13M
1 W Prestazione:
-5.39%
1M Prestazione:
+4.31%
6M Prestazione:
+87.91%
1 anno Prestazione:
+48.96%
Intervallo 1D:
$38.44
$41.38
Intervallo di 1 settimana:
$38.44
$43.88
Portata 52W:
$18.61
$46.00
Veracyte Inc Stock (VCYT) Company Profile
Nome
Veracyte Inc
Settore
Industria
Telefono
(650) 243-6300
Indirizzo
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta VCYT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
40.89 | 3.17B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-16 | Iniziato | UBS | Buy |
| 2024-10-10 | Iniziato | Guggenheim | Buy |
| 2024-02-23 | Reiterato | Needham | Buy |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2021-11-18 | Ripresa | Goldman | Buy |
| 2021-06-15 | Iniziato | Raymond James | Outperform |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2019-07-31 | Iniziato | Lake Street | Buy |
| 2019-07-02 | Iniziato | Needham | Buy |
| 2018-11-29 | Downgrade | Janney | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-07 | Downgrade | Janney | Buy → Neutral |
| 2017-11-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | Ripresa | BTIG Research | Buy |
| 2016-11-14 | Ripresa | Leerink Partners | Outperform |
| 2015-12-18 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-11 | Reiterato | Leerink Partners | Outperform |
| 2013-11-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Veracyte Inc Borsa (VCYT) Ultime notizie
Barclays PLC Buys 85,033 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
HighTower Advisors LLC Takes $554,000 Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories - Zacks Investment Research
Veracyte CEO Marc Stapley sells shares worth $242,736 By Investing.com - Investing.com Canada
Veracyte CEO Marc Stapley sells shares worth $242,736 - Investing.com India
Lord Abbett & CO. LLC Purchases New Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
The Zacks Analyst Blog Highlights McKesson, Doximity and Veracyte - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Fmr LLC - MarketBeat
US Exchange: 3 Stocks That May Be Trading Below Fair Value - Simply Wall St
Jane Street Group LLC Raises Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now - MSN
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer Diagnostics - Yahoo! Voices
Veracyte (VCYT) Shares Rebounded in Q3 - Insider Monkey
Neo Ivy Capital Management Buys Shares of 24,116 Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen - Yahoo Finance
Those who invested in Veracyte (NASDAQ:VCYT) a year ago are up 68% - Yahoo Finance
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar - Yahoo Finance
Veracyte: Getting Frothy (NASDAQ:VCYT) - Seeking Alpha
Zacks Investment Management Makes New $1.12 Million Investment in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Wellington Management Group LLP Cuts Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Cerity Partners LLC Purchases New Shares in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
48,193 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by XTX Topco Ltd - MarketBeat
Verition Fund Management LLC Takes $1.32 Million Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Insider Sell Alert: Phillip Febbo Sells Shares of Veracyte Inc (VCYT) - GuruFocus.com
Veracyte's chief scientific officer sells $173,447 in stock By Investing.com - Investing.com Australia
Benjamin Edwards Inc. Boosts Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte's chief scientific officer sells $173,447 in stock - Investing.com India
Veracyte SVP McGuire sells $823,178 in stock By Investing.com - Investing.com Australia
Veracyte SVP McGuire sells $823,178 in stock - Investing.com India
Charles Schwab Investment Management Inc. Decreases Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte, Inc. (NASDAQ:VCYT) Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Veracyte's Decipher Test Makes Breakthrough: Only Gene Expression Test in 2025 NCCN Prostate Cancer Guidelines - StockTitan
Goldman Sachs Downgrades Veracyte (VCYT) - MSN
Navigating 9 Analyst Ratings For Veracyte - Benzinga
Veracyte CFO Rebecca Chambers sells $302,621 in stock By Investing.com - Investing.com South Africa
Veracyte stock downgraded by Goldman Sachs, target reduced amid slowing growth - Investing.com
Veracyte stock soars to 52-week high of $44.48 amid robust growth - Investing.com Canada
Erste Asset Management GmbH Takes $574,000 Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Veracyte's chief accounting officer sells shares worth $41,452 By Investing.com - Investing.com Australia
Veracyte CFO Rebecca Chambers sells $302,621 in stock - Investing.com
Veracyte stock soars to 52-week high of $44.48 amid robust growth By Investing.com - Investing.com South Africa
Parkman Healthcare Partners LLC Sells 80,215 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte's chief accounting officer sells shares worth $41,452 - Investing.com
VCYT (Veracyte) 3-Year Revenue Growth Rate : 31.10% (As of Sep. 2024) - GuruFocus.com
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St
PDT Partners LLC Takes $2.38 Million Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Vinva Investment Management Ltd Buys Shares of 15,266 Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte Inc Azioni (VCYT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):